These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18011727)

  • 1. THE COST OF NON-FATAL DISEASE.
    Am J Public Health (N Y); 1926 Jan; 16(1):51-2. PubMed ID: 18011727
    [No Abstract]   [Full Text] [Related]  

  • 2. Average medical cost of fatal and non-fatal injuries by type in the USA.
    Peterson C; Xu L; Florence C
    Inj Prev; 2021 Feb; 27(1):24-33. PubMed ID: 31888976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong.
    Chau J; Cheung BM; McGhee SM; Lauder IJ; Lau CP; Kumana CR
    Hong Kong Med J; 2001 Dec; 7(4):360-8. PubMed ID: 11773670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
    Greenhalgh J; Bagust A; Boland A; Saborido CM; Fleeman N; McLeod C; Dundar Y; Dickson R; Proudlove C; Kolamunnage-Dona R; Fisher M
    Health Technol Assess; 2010 May; 14 Suppl 1():31-8. PubMed ID: 20507801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
    Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
    BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial.
    Manceur AM; Durkin M; Kharat A; Bookhart B; Lafeuille MH; Pilon D; Fakih I; Lefebvre P
    Curr Med Res Opin; 2020 Apr; 36(4):563-570. PubMed ID: 31916465
    [No Abstract]   [Full Text] [Related]  

  • 7. Influenza disease burden among potential target risk groups for immunization in South Africa, 2013-2015.
    Tempia S; Walaza S; Moyes J; McMorrow ML; Cohen AL; Edoka I; Fraser H; Treurnicht FK; Hellferscee O; Wolter N; von Gottberg A; McAnerney JM; Dawood H; Variava E; Cohen C
    Vaccine; 2020 Jun; 38(27):4288-4297. PubMed ID: 32389494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of fatal and non-fatal road traffic injuries in Guadalajara Metropolitan Area and Jalisco, Mexico.
    Pérez-Núñez R; Avila-Burgos L; Híjar-Medina M; Pelcastre-Villafuerte B; Celis A; Salinas-Rodríguez A
    Inj Prev; 2011 Oct; 17(5):297-303. PubMed ID: 21486986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The direct costs of fatal and non-fatal falls among older adults - United States.
    Burns ER; Stevens JA; Lee R
    J Safety Res; 2016 Sep; 58():99-103. PubMed ID: 27620939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based incidence and cost of non-fatal injuries in Iran: a consistent under-recognized public health concern.
    Hafezi-Nejad N; Rahimi-Movaghar A; Motevalian A; Amin-Esmaeili M; Sharifi V; Hajebi A; Radgoodarzi R; Hefazi M; Eslami V; Karimi H; Saadat S; Mohammad K; Rahimi-Movaghar V
    Public Health; 2015 May; 129(5):483-92. PubMed ID: 25749671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness analysis of a smoke alarm giveaway program in Oklahoma City, Oklahoma.
    Haddix AC; Mallonee S; Waxweiler R; Douglas MR
    Inj Prev; 2001 Dec; 7(4):276-81. PubMed ID: 11770651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic costs of motor vehicle crashes involving teenaged drivers in Kentucky, 1994.
    Goldstein LA; Spurlock CW; Kidd PS
    Inj Prev; 1997 Sep; 3(3):200-6. PubMed ID: 9338832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated total costs from non-fatal and fatal bicycle crashes in the USA: 1997-2013.
    Gaither TW; Sanford TA; Awad MA; Osterberg EC; Murphy GP; Lawrence BA; Miller TR; Breyer BN
    Inj Prev; 2018 Apr; 24(2):135-141. PubMed ID: 28572269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effective management of malignant potentially fatal asthma.
    Levenson T; Grammer LC; Yarnold PR; Patterson R
    Allergy Asthma Proc; 1997; 18(2):73-8. PubMed ID: 9134063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of venous thrombosis and thromboembolism: prevention and treatment.
    Bick RL
    Surg Technol Int; 2002 Sep; 10():226-36. PubMed ID: 12384886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of respiratory pathogens to fatal and non-fatal respiratory hospitalizations: a pilot study of Taqman Array Cards (TAC) in Kenya.
    Njuguna HN; Chaves SS; Emukule GO; Nyawanda B; Omballa V; Juma B; Onyango CO; Mott JA; Fields B
    BMC Infect Dis; 2017 Aug; 17(1):591. PubMed ID: 28841843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
    Zomer E; Si S; Hird TR; Liew D; Owen AJ; Tonkin A; Reid CM; Ademi Z
    Eur J Prev Cardiol; 2019 May; 26(8):858-868. PubMed ID: 30526023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of a dealer's intervention in retrofitting rollover protective structures.
    Myers ML; Cole HP; Westneat SC
    Inj Prev; 2005 Jun; 11(3):169-73. PubMed ID: 15933410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.
    Penn MS; Yenikomshian MA; Cummings AK; Klemes A; Damron JM; Purvis S; Beidelschies M; Birnbaum HG
    J Med Econ; 2015; 18(7):483-91. PubMed ID: 25763924
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.